USP7 and nonpapillary renal cell carcinoma: In this study, we have identified a novel FUBPs–USP7–HIF2α regulatory axis that modulates the progression of ccRCC, and developed a potential therapeutic strategy of ccRCC by combinational usage of USP7 inhibitor and afatinib (Fig. 8i).